Design, Synthesis, and Biological Evaluation of Cyclic and Acyclic Nitrobenzylphosphoramide Mustards for E. coli Nitroreductase Activation
摘要:
In efforts to obtain anticancer prodrugs for antibody-directed or gene-directed enzyme prodrug therapy using E. coli nitroreductase, a series of nitrobenzylphosphoramide mustards were designed and synthesized incorporating a strategically placed nitro group in a position para to the benzylic carbon for reductive activation. All analogues were good substrates of E. coli nitroreductase with half-lives between 2.9 and 11.9 min at pH 7.0 and 37 degrees C. Isomers of the 4-nitrophenylcyclophosphamide analogues 3 and 5 with a benzylic oxygen para to the nitro group showed potent selective cytotoxicity in nitroreductase (NTR) expressing cells, while analogues 4 and 6 with a benzylic nitrogen para to the nitro group showed little selective cytotoxicity despite their good substrate activity. These results suggest that good substrate activity and the benzylic oxygen are both required for reductive activation of 4-nitrophenylcyclophosphamide analogues by E. coli nitroreductase. Isomers of analogue 3 showed 23000-29000 x selective cytotoxicity toward NTR-expressing V79 cells with an IC50 as low as 27 nM. They are about as active as and 3-4x more selective than 5-aziridinyl-2,4-dinitrobenzamide (CB1954). The acyclic 4-nitrobenzylphosphoramide mustard ((+/-)-7) was found to be the most active and most selective compound for activation by NTR with 170000x selective cytotoxicity toward NTR-expressing V79 cells and an IC50 of 0.4 nM. Compound (+/-)-7 also exhibited good bystander effect compared to 5-aziridinyl-2,4-dinitrobenzamide. The low IC50, high selectivity, and good bystander effects of nitrobenzylphosphoramide mustards in NTR-expressing cells suggest that they could be used in combination with E. coli nitroreductase in enzyme prodrug therapy.
Design, Synthesis, and Biological Evaluation of Cyclic and Acyclic Nitrobenzylphosphoramide Mustards for E. coli Nitroreductase Activation
摘要:
In efforts to obtain anticancer prodrugs for antibody-directed or gene-directed enzyme prodrug therapy using E. coli nitroreductase, a series of nitrobenzylphosphoramide mustards were designed and synthesized incorporating a strategically placed nitro group in a position para to the benzylic carbon for reductive activation. All analogues were good substrates of E. coli nitroreductase with half-lives between 2.9 and 11.9 min at pH 7.0 and 37 degrees C. Isomers of the 4-nitrophenylcyclophosphamide analogues 3 and 5 with a benzylic oxygen para to the nitro group showed potent selective cytotoxicity in nitroreductase (NTR) expressing cells, while analogues 4 and 6 with a benzylic nitrogen para to the nitro group showed little selective cytotoxicity despite their good substrate activity. These results suggest that good substrate activity and the benzylic oxygen are both required for reductive activation of 4-nitrophenylcyclophosphamide analogues by E. coli nitroreductase. Isomers of analogue 3 showed 23000-29000 x selective cytotoxicity toward NTR-expressing V79 cells with an IC50 as low as 27 nM. They are about as active as and 3-4x more selective than 5-aziridinyl-2,4-dinitrobenzamide (CB1954). The acyclic 4-nitrobenzylphosphoramide mustard ((+/-)-7) was found to be the most active and most selective compound for activation by NTR with 170000x selective cytotoxicity toward NTR-expressing V79 cells and an IC50 of 0.4 nM. Compound (+/-)-7 also exhibited good bystander effect compared to 5-aziridinyl-2,4-dinitrobenzamide. The low IC50, high selectivity, and good bystander effects of nitrobenzylphosphoramide mustards in NTR-expressing cells suggest that they could be used in combination with E. coli nitroreductase in enzyme prodrug therapy.
Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation
申请人:——
公开号:US20040214798A1
公开(公告)日:2004-10-28
The present invention relates to nitroaryl-substituted phosphoramide prodrug compounds and methods of producing the same for use in targeting and inhibiting undesirable cell growth or proliferation.
本发明涉及硝基芳基取代的磷酰胺前药化合物及其制备方法,用于靶向和抑制不良细胞生长或增殖。
[EN] AN IMPROVED PROCESS FOR THE PREPARATION OF ZOLMITRIPTAN<br/>[FR] PROCÉDÉ DE PRÉPARATION AMÉLIORÉ DE ZOLMITRIPTAN
申请人:MATRIX LAB LTD
公开号:WO2008018090A2
公开(公告)日:2008-02-14
[EN] Disclosed herein the process for producing pure" Zolmitriptan employing improved reaction conditions which excluded the use of column chromatography. [FR] La présente invention concerne un procédé permettant de produire du Zolmitriptan pur, le procédé étant mis en oevre dans des conditions réactionnelles améliorées qui excluent l'utilisation d'une chromatographie sur colonne.
Design, Synthesis, and Biological Evaluation of Cyclic and Acyclic Nitrobenzylphosphoramide Mustards for <i>E. </i><i>c</i><i>oli </i>Nitroreductase Activation
作者:Yongying Jiang、Jiye Han、Chengzhi Yu、Simon O. Vass、Peter F. Searle、Patrick Browne、Richard J. Knox、Longqin Hu
DOI:10.1021/jm051246n
日期:2006.7.1
In efforts to obtain anticancer prodrugs for antibody-directed or gene-directed enzyme prodrug therapy using E. coli nitroreductase, a series of nitrobenzylphosphoramide mustards were designed and synthesized incorporating a strategically placed nitro group in a position para to the benzylic carbon for reductive activation. All analogues were good substrates of E. coli nitroreductase with half-lives between 2.9 and 11.9 min at pH 7.0 and 37 degrees C. Isomers of the 4-nitrophenylcyclophosphamide analogues 3 and 5 with a benzylic oxygen para to the nitro group showed potent selective cytotoxicity in nitroreductase (NTR) expressing cells, while analogues 4 and 6 with a benzylic nitrogen para to the nitro group showed little selective cytotoxicity despite their good substrate activity. These results suggest that good substrate activity and the benzylic oxygen are both required for reductive activation of 4-nitrophenylcyclophosphamide analogues by E. coli nitroreductase. Isomers of analogue 3 showed 23000-29000 x selective cytotoxicity toward NTR-expressing V79 cells with an IC50 as low as 27 nM. They are about as active as and 3-4x more selective than 5-aziridinyl-2,4-dinitrobenzamide (CB1954). The acyclic 4-nitrobenzylphosphoramide mustard ((+/-)-7) was found to be the most active and most selective compound for activation by NTR with 170000x selective cytotoxicity toward NTR-expressing V79 cells and an IC50 of 0.4 nM. Compound (+/-)-7 also exhibited good bystander effect compared to 5-aziridinyl-2,4-dinitrobenzamide. The low IC50, high selectivity, and good bystander effects of nitrobenzylphosphoramide mustards in NTR-expressing cells suggest that they could be used in combination with E. coli nitroreductase in enzyme prodrug therapy.